Enterofuryl, 200 mg capsules 16 pcs

Entrofuryl^® is a broad-spectrum antimicrobial drug with no systemic action used for treatment of diarrhea of infectious etiology. The drug Entherofuryl ^® contains the active substance nifuroxazide, a drug of the group of 5-nitrofuran derivatives.

The drug has a bactericidal and bacteriostatic effect against most pathogens of acute intestinal infections. Antimicrobial action of nifuroxazide is dose-dependent: thus, low and medium doses of the drug have a bacteriostatic effect against pathogenic microflora, and high – bactericidal.

Bacteriostatic mechanism of action of the drug is associated with inhibition of activity of the enzyme dehydrogenase, which leads to disruption of the normal course of synthesis of vital compounds in the cell of the microorganism.

Thus, due to the effect of nifuroxazide on a microorganism cell the respiratory chain is broken and the tricarboxylic acid cycle is suppressed. In addition, Enterofuryl^® inhibits protein synthesis in the microorganism cell and inhibits other biochemical processes in the bacterial cell. Thus, the microorganism cell loses its ability to reproduce.

Indications

Intestinal infections, Colic, Salmonellosis, Poisoning, DiarrheaDiarrhea of bacterial origin.

Active ingredient

Nifuroxazide

Composition

1 capsule contains:

Active substance:

Nifuroxazide 200 mg,

Supplementary substances:

sucrose, 71 mg;

corn starch, 68 mg;

MCC – 9 mg;

Magnesium stearate – 2 mg,

Shell:

gelatin;

titanium dioxide;

iron oxide yellow dye.

How to take, the dosage

Ingestion. Therapy with nifuroxazide should not last more than 7 days.

Adults and children over 7 years are given 1 capsule (200 mg) 4 times daily, the daily dose is 800 mg.

Children 3-7 years are given 1 capsule (200 mg) 3 times daily, the daily dose is 600 mg.

Special Instructions

In the treatment of diarrhea, rehydration therapy (oral or intravenous) should be given concomitantly with nifuroxazide therapy according to the patient’s condition and the intensity of the diarrhea.

The use of alcohol during therapy with nifuroxazide is prohibited.

Before prescribing the suspension in infants, it is necessary to rule out congenital deficiency of sucrose digesting enzymes.

Impact on the ability to drive vehicles and operate machinery.

The drug does not affect psychomotor performance and ability to drive vehicles and operate machinery.

Contraindications

Children under 3 years of age. hypersensitivity to nitrofuran derivatives or other components of the drug; fructose intolerance, glucose-galactose malabsorption syndrome or insufficiency of sucrose and isomaltase.

Side effects

Allergic reactions nausea, vomiting (anaphylactic shock, rash, urticaria, Quincke’s edema).

Overdose

The drug is not absorbed from the gastrointestinal tract and does not enter the systemic circulation.

The symptoms of overdose are not known.

In case of overdose, gastric lavage and symptomatic treatment are recommended.

Pregnancy use

The use of the drug Entrofulil in pregnancy is possible only in cases when the expected benefits of therapy for the mother exceed the potential risk to the fetus.

Entrofuryl is not absorbed from the gastrointestinal tract and does not enter the systemic circulation, but the drug may be used during lactation only with strict indications, in this case the question about stopping breast-feeding should be solved.

Similarities

Enterofuryl, Nifuroxazid, Stopdiar, Ecofuryl, Adisord, Nifural, Elufor